Use of granulocyte colony-stimulating factor after high-dose chemotherapy and autologous peripheral blood stem cell transplantation: What is the optimal timing?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 1, 2001, Pages 19-25

  Ener, Rasih Atilla ^a   Meglathery, Sharon B ^a,b   Cuhaci, Bulent ^a,b   Topolsky, David ^c   Styler, Michael J ^a   Crilley, Pamela ^a   Brodsky, Isadore ^a   Benham Kahn, S ^a   King, Reginald S ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NONE

Author keywords

Autologous peripheral blood stem cell transplantation; Clinical outcomes; Granulocyte colony stimulating factor; High dose chemotherapy; Neutrophil recovery; Optimal timing; Posttransplant hospital days; Total hospital days

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; LYMPHOCYTE COUNT; MALE; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; STEM CELL; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENGTH OF STAY; LEUKOCYTE COUNT; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING;

EID: 0035113514     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200102000-00003     Document Type: Article

References (40)

1. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy
2. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison
3. + cells in autologous stem cell transplantation for breast cancer
4. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor
5. + hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor
6. Recombinant human interleukin-3 stimulation of hematopoiesis in humans: Loss of responsiveness with differentiation in the neutrophilic myeloid series
7. Direct proliferative actions of stem cell factor on murine bone marrow cells in vitro: Effects of combination with colony-stimulating factors
8. The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocyte colony-stimulating factor
9. Effect of interleukin-6 (IL-6) on the differentiation and proliferation of murine and human hematopoietic progenitors
10. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells: Identification as granulocyte colony-stimulating factor
11. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium
12. Effect of granulocyte colony stimulating factor on neutropenia induced by cytoxic chemotherapy
13. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium
14. Phase I/II study of recombinant granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer
15. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression
16. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome
17. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis
18. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes
19. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: Toxicity, pharmacokinetics, and hematological effects
20. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes-a phase I/II trial
21. Effect of recombinant granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation
22. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies
23. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation
24. Recombinant granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for lymphoid cancer
25. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease
26. Randomized study of recombinant human granulocyte colony-stimulating factor after high dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies
27. Randomized study of growth factors post-peripheral blood stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit
28. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial
29. Synergistic factors for stem cell proliferation: Further studies of the target stem cells and the mechanism of stimulation by interleukin-1, interleukin-6, and granulocyte colony-stimulating factor
30. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors
31. Colony formation of clone-sorted human hematopoietic progenitors
32. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: Parameters affecting bone marrow engraftment
33. Administration of granulocyte colony-stimulating factor from day 7 after autologous bone marrow transplantation: Effects on neutropenia and duration of hospitalization
34. Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT
35. Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is costeffective
36. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation: A prospective randomized study
37. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: Effect on granulocyte recovery
38. Administration of G-CSF can be delayed after transplantation of autologous G-CSF primed blood stem cells: A randomized study
39. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation
40. Effect of G-CSF timing on hematopoetic recovery following high dose chemotherapy and autologous blood stem cell re-infusion